This week, we continue our series on Orphan Drugs by looking at a few ways that pharmaceutical companies game the system, and shoehorn their drugs into qualifying for orphan drug status, and therefore greater patent protection. All these methods tend to translate to higher costs for consumers. Sources can be found in the posts friend-of-the-show Nick Bagley has written on the subject: http://theincidentaleconomist.com/wordpress/tag/orphan-drugs/ John Green -- Executive Producer Stan Muller -- Director, Producer Aaron Carroll -- Writer Mark Olsen – Graphics Meredith Danko – Social Media http://www.twitter.com/aaronecarroll http://www.twitter.com/crashcoursestan http://www.twitter.com/johngreen http://www.twitter.com/olsenvideo And the housekeeping: 1) You can support Healthcare Triage on Patreon: http://vid.io/xqXr Every little bit helps make the show better! 2) Check out our Facebook page: http://goo.gl/LnOq5z 3) We still have merchandise available at http://www.hctmerch.com